HOME >> BIOLOGY >> NEWS
Cognitive therapy for schizophrenia: Hope for those whom drugs havent helped

DENVER, CO In an about face, the British National Health Service recently adopted cognitive therapy as a valid and reimbursable treatment for schizophrenia, a disease of the mind that traditionally has been thought of as unresponsive to all but powerful drug therapies.

Researchers at the AAAS Annual Meeting in Denver today described the groundbreaking approach that led British public health officials to permit the use of psychological therapy--in conjunction with drug therapy--for people with schizophrenia, a disease that affects one percent of the world's population.

"The magnitude of the effect of this therapy is similar to the effects of the newest anti-psychotic medication average reductions in symptoms of 20-40% - and without the side-effects that medications typically cause," said Philippa Garety, professor of clinical psychology at Guy's, King's and St Thomas' School of Medicine and the Institute of Psychiatry and head of psychology for the local South London mental health services.

According to Garety, cognitive behavioural therapy helps people with schizophrenia identify the negative thoughts that drive their emotions. She called the approach, "a joint process of inquiry, in which therapist and client together test out new ways of thinking and behaving."

The discussion takes place against the backdrop of studies that suggest that genetic vulnerability to Schizophrenia is more widespread in the general population than previously thought, as high as 10 to 20 percent, according to another panelist and leading geneticist, Robert Freedman, Professor and Chair of the Department of Psychiatry at the University of Colorado Health Sciences Center.

"From the perspective of education about stigma against mental illness, these findings suggest that schizophrenia is not the result of a rare aberration, but rather the result of a complex association between common elements," Freedman said. "Some of these common elements are lik
'"/>


13-Feb-2003


Page: 1 2

Related biology news :

1. Cognitive performance influenced by gene for prion protein (also affected by mad cow disease)
2. Good News: Cognitive decline after bypass surgery mostly temporary and reversible
3. Cognitive abilities increase significantly with time in most prematurely born children
4. Cognitive testing reduces risks of procedure for brain arteriovenous malformations
5. Study Finds Evidence Linking The Brains Cognitive Control Regions With Stress Control Regions
6. Targeted therapy knocks out pediatric brain cancer in mice
7. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
8. Columbia research to examine gene influence on severity of peridontal disease, therapy response
9. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
10. The search for a kinder, gentler chemotherapy
11. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart

Post Your Comments:
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: